Merrill Lynch analyst Michael Cherny maintained a Buy rating on Allscripts (NASDAQ:MDRX) on Wednesday, setting a price target of $16.5, which is approximately 16.20% above the present share price of $14.2.
Cherny expects Allscripts to post earnings per share (EPS) of $0.00 for the fourth quarter of 2020.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Allscripts, with an average price target of $12.83.
The analysts price targets range from a high of $17 to a low of $9.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $402.03 million and a net profit of $9.59 million. The company's market cap is $2.24 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.0% and a 60.81% success rate.
Allscripts Healthcare Solutions, Inc. engages in the provision of clinical, financial, connectivity, information solutions, and related professional services. It operates through the following segments: Clinical and Financial Solutions; Population Health; and Netsmart. The Clinical and Financial Solutions segment involves in the sale of clinical software applications and financial and information solutions. The Population Health segment offers health management and coordinated care solutions. The Netsmart segment operates in the home care and behavioral healthcare information technology field throughout the United States. The company was founded in 1986 and is headquartered in Chicago, IL.